查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138302

布魯氏菌病疫苗全球市場-2022-2029

Global Brucellosis Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

市場參與者的努力將在預測期內繼續支持市場增長

市場參與者正在採取多項舉措，在不發達國家啟動宣傳計劃，以提高人們對牲畜疫苗接種的認識，以維護動物健康和福利。 2018 年 12 月，勃林格殷格翰發起了“最後一英裡”計劃，通過在難以到達的地區提供動物健康資源，專注於重要的動物健康挑戰。該倡議針對綿羊、山羊和牛等反芻動物，併計劃擴展到家禽。該公司正在讚助這項由全球家畜獸藥聯盟 (GALVmed) 支持並由 BMGF 贊助的倡議，以彌合非洲小農在獲得、獲得和認識動物健康解決方案方面的差距。

2019 年 2 月，糧農組織與漁業和畜牧業部合作發起了牛疫苗接種運動。該運動解決了已導致 3,000 多頭牛死亡的有症狀炭疽病的爆發。糧農組織將從 2017 年開始擴大規模，以應對日益普遍的動物疾病，目標是拯救約 900 萬隻動物。大約 1,000 名以社區為基礎的動物衛生工作者接受了培訓，通過糧農組織的牲畜應急計劃進行例行檢查和牲畜疫苗接種。此外，2019 年 9 月，印度政府宣布了一項來自印度馬圖拉的約 18 億美元的牲畜疫苗接種計劃。該倡議旨在在未來五年內控制牲畜流行病，主要是布魯氏菌病和口蹄疫（FMD）。

全球布魯氏菌病疫苗市場報告提供大約 73 個市場數據表、57 個數字和 170 頁結構

目錄

第一章調查方法及範圍

  • 調查方法
  • 市場範圍

第 2 章主要趨勢和發展

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按處理方法劃分的市場細分
  • 按診斷劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
    • 約束因素
    • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措

第 7 章品種

  • 羊
  • 牛
  • 山羊

第 8 章治療

  • 抗生素
  • 疫苗

第 9 章診斷

  • 血清學檢測
  • 分子生物學測試
  • 骨髓活檢
  • 磁共振成像 (MRI)
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 競爭對手戰略分析
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • AniCon Labor GmbH
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Biogenesis-Bago
  • Calier & Biologicos Laverlam
  • Colorado Serum Company
  • Hester Biosciences Limited
  • Heska Corporation
  • Indian Immunologicals Ltd.
  • Lohmann Animal Health
  • Chengdu Agricultural Machinery Plant
  • Lanzhou Biological Pharmaceutical Plant
  • Inner Mongolia Biological Pharmaceutical Plant
  • Chinese Academy of Agricultural Science

第13章 DataM

簡介目錄
Product Code: DMHCIT2964

Market Overview

The global brucellosis vaccines market was valued at USD 323.45 million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.5% during the forecast period (2022-2029).

The livestock or farm animal's category encompasses cattle, sheep, and goats that are vaccinated to protect against brucellosis diseases. The first dose of this vaccine is given at the age of 4-8 months of calves. It is the most widely used vaccine around the world. The Livestock Vaccine Innovation Fund (LVIF) project collaborates between the J. Craig Venter Institute and the International Livestock Research Institute to promote this vaccine. The LVIF enables improved health of livestock, as farmers' livelihoods depend on livestock. LVIF is an initiative taken by the Bill & Melinda Gates Foundation, Global Affairs Canada, and International Development Research Center (IDRC). It represents a joint investment over five years to reinforce the production, development, and commercialization of innovative vaccines to prevent livestock diseases in sub-Saharan Africa and South and Southeast Asia. The rising prevalence of brucellosis diseases in livestock and the increasing consumption of meat products are some factors that are expected to propel market growth.

Market Dynamics: Initiatives by market players will continue supporting the growth of the market during the forecast period

The market players are taking several initiatives by launching awareness programs in underdeveloped countries to raise awareness about livestock vaccination to maintain animal health and welfare. In December 2018, Boehringer Ingelheim launched the 'LastMile' initiative to focus on crucial animal health challenges by making animal medical resources available in hard-to-reach areas. The initiative targets ruminants, such as sheep, goats, and cattle, and will further expand to poultry. The company started this initiative with support from the Global Alliance for Livestock Veterinary Medicines (GALVmed) and was sponsored by BMGF to bridge gaps in access, availability, and awareness of animal healthcare solutions for smallholder farmers in Africa.

In February 2019, FAO launched a cattle vaccination campaign through collaboration with the Ministry of Fisheries and Livestock. The campaign was intended to address the outbreak of symptomatic anthrax, which has caused the loss of more than 3,000 cattle. The FAO aims to protect nearly 9 million animals from combating increasingly common animal diseases, scaling up from 2017. Around 1,000 community-based animal health workers have been trained and are carrying-out routine check-ups and vaccinating livestock through FAO's Emergency Livestock Response Program. Additionally, the Indian government declared a nearly $1.8 billion livestock vaccination scheme in September 2019 from Mathura, India. This initiative is intended to control livestock diseases, primarily brucellosis and foot and mouth disease (FMD), in the next five years.

Market Segmentation: The cattle segment accounted for the highest share in global brucellosis vaccines market

Cattle contribute a significant share in the brucellosis vaccines market. The market players are continuously offering novel products for the cattle. In September 2018, Boehringer Ingelheim launched a new respiratory vaccine, Bovalto Respi Intranasal, for cattle to protect against viruses Parainfluenza 3 Virus (PI3V) and Bovine Respiratory Syncytial Virus (BRSV). In March 2015, Boehringer Ingelheim launched a new vaccine, Bovela against Bovine Viral Diarrhea (BVD), in Europe for active immunization of cattle against both genotypes of the virus (BVDV-1 and BVDV-2). Besides, Zoetis Inc., in April 2018, expanded its manufacturing and research unit to Suzhou, China, to focus on the vaccines for cattle, pigs, fish, and companion animals.

Based on the treatment, the brucellosis vaccine market has been bifurcated into vaccines and antibiotics. Vaccination plays a considerable role in maintaining the proper health of livestock. The high consumption of meat products globally is further contributing to the livestock vaccine's growth, including the brucellosis vaccines market. Therefore, it contributes a significant share in the development of the brucellosis vaccines market across the globe. Several companies are offering and continuously researching the field of brucellosis vaccine.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global brucellosis vaccines market and is expected to retain its position during the forecast period. The US contributed over XX% to the North American brucellosis vaccines market in 2021. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

The Asia Pacific is estimated to grow at a considerable growth rate in the brucellosis vaccines market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Such huge stats for animal husbandry are expected to grow the brucellosis vaccines market during the forecast period.

Competitive Landscape:

The Brucellosis vaccines market is fragmented due to multiple companies' availability. Some of the major key players in the market are AbbVie, Inc., AstraZeneca PLC, Bayer AG, BeiGene, CARsgen Therapeutics, CStone Pharmaceuticals Co., Ltd. and GlaxoSmithKline PLC, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the Brucellosis Vaccines market globally. In July 2020, AstraZeneca and Merck & Co., Inc. announced that Lynparza (olaparib) had been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. This approval further provides the company with a significant opportunity to sustain a substantial European pancreatic cancer drugs market position. In June 2020, AbbVie collaborated with Jacobio Pharmaceuticals to develop and commercialize SHP2 inhibitors that act on an important node in cancer and immune cells. In January 2022, AbbVie Announced U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for the treatment of non-small cell lung cancer. In October 2021, US FDA approved Roche's Tecentriq as an adjuvant treatment for people with early non-small cell lung cancer. It is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

COVID-19 Impact: Negative impact on the global Brucellosis Vaccines market

The outbreak of COVID-19 has certainly impacted the global brucellosis vaccines market. The lockdown has compelled the veterinaries to close their operations, or even if the vets are open, the public was afraid to visit vets for vaccination during the meantime. Besides, the consumption of meat and dairy products has decreased during the outbreak, which, in turn, has impacted the expansion of livestock across the globe. Therefore, the brucellosis vaccines market is expected to foresee a considerable decline in 2020.

The global brucellosis vaccines market report would provide an access to approximately 73 market data tables, 57 figures and 170 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Species
  • 3.2. Market Snippet by Treatment
  • 3.3. Market Snippet by Diagnosis
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Species

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Species Segment
    • 7.1.2. Market attractiveness index, By Species Segment
  • 7.2. Sheep *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Cattle
  • 7.4. Goat

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Treatment Segment
    • 8.1.2. Market attractiveness index, By Treatment Segment
  • 8.2. Antibiotics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccines

9. By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnosis Segment
    • 9.1.2. Market attractiveness index, By Diagnosis Segment
  • 9.2. Serological Tests*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Molecular Techniques
  • 9.4. Bone Marrow Biopsy
  • 9.5. Magnetic Resonance Imaging (MRI)
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis

11. Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. AniCon Labor GmbH*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bayer AG
  • 12.3. Boehringer Ingelheim International GmbH
  • 12.4. Biogenesis-Bago
  • 12.5. Calier & Biologicos Laverlam
  • 12.6. Colorado Serum Company
  • 12.7. Hester Biosciences Limited
  • 12.8. Heska Corporation
  • 12.9. Indian Immunologicals Ltd.
  • 12.10. Lohmann Animal Health
  • 12.11. Chengdu Agricultural Machinery Plant
  • 12.12. Lanzhou Biological Pharmaceutical Plant
  • 12.13. Inner Mongolia Biological Pharmaceutical Plant
  • 12.14. Chinese Academy of Agricultural Science
  • List not Exhaustive*

13. DataM

  • 13.1. Appendix
  • 13.2. About us and services
  • 13.3. Contact us